S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:ASND

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

$151.17
+2.73 (+1.84%)
(As of 03/28/2024 ET)
Today's Range
$144.66
$151.59
50-Day Range
$129.20
$159.40
52-Week Range
$64.33
$161.00
Volume
295,863 shs
Average Volume
295,281 shs
Market Capitalization
$8.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$174.14

Ascendis Pharma A/S MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
15.2% Upside
$174.14 Price Target
Short Interest
Bearish
5.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.97mentions of Ascendis Pharma A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.16) to ($0.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.88 out of 5 stars

Medical Sector

849th out of 939 stocks

Pharmaceutical Preparations Industry

401st out of 444 stocks

ASND stock logo

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Stock Price History

ASND Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
Ascendis Pharma A/S ADR
Ascendis Pharma A/S - ADR
How Is The Market Feeling About Ascendis Pharma?
Ascendis Pharma price target raised by $18 at Wedbush, here's why
Ascendis Pharma: Strong Buy on Robust Sales and Innovative Pipeline
See More Headlines
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/29/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ASND
Employees
879
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$174.14
High Stock Price Target
$260.00
Low Stock Price Target
$113.00
Potential Upside/Downside
+15.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-521,070,000.00
Net Margins
-180.61%
Pretax Margin
-177.77%
Return on Equity
-16,574.15%

Debt

Sales & Book Value

Annual Sales
$288.08 million
Book Value
($2.73) per share

Miscellaneous

Free Float
34,624,000
Market Cap
$8.72 billion
Optionable
Optionable
Beta
0.52
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Jan Moller Mikkelsen (Age 64)
    President, CEO, Member of Executive Board & Executive Director
  • Mr. Scott T. Smith (Age 50)
    CFO, Executive VP & Member of Executive Board
  • Ms. Lotte Sonderbjerg (Age 63)
    Executive VP, Chief Administrative Officer & Member of the Executive Board
  • Mr. Michael Wolff Jensen L.L.M. (Age 53)
    Executive VP, Chief Legal Officer & Member of the Executive Board
  • Mr. Timothy J. Lee
    Senior Director of Investor Relations
  • Mr. Flemming Steen Jensen (Age 63)
    Executive Vice President of Product Supply & Quality
  • Dr. Kennett Sprogoe Ph.D. (Age 45)
    Executive VP and Head of Research & Product Development
  • Dr. Stina Singel M.D. (Age 50)
    Ph.D., Executive VP & Head of Clinical Development for Oncology
  • Mr. Joseph Kelly (Age 55)
    Head of U.S. Commercial of Endocrinology
  • Mr. Scott A. Holmes
    Head of Global Commercial Strategy of Endocrinology

ASND Stock Analysis - Frequently Asked Questions

Should I buy or sell Ascendis Pharma A/S stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ASND shares.
View ASND analyst ratings
or view top-rated stocks.

What is Ascendis Pharma A/S's stock price target for 2024?

10 equities research analysts have issued 12-month target prices for Ascendis Pharma A/S's stock. Their ASND share price targets range from $113.00 to $260.00. On average, they expect the company's share price to reach $174.14 in the next year. This suggests a possible upside of 15.2% from the stock's current price.
View analysts price targets for ASND
or view top-rated stocks among Wall Street analysts.

How have ASND shares performed in 2024?

Ascendis Pharma A/S's stock was trading at $125.95 on January 1st, 2024. Since then, ASND shares have increased by 20.0% and is now trading at $151.17.
View the best growth stocks for 2024 here
.

When is Ascendis Pharma A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ASND earnings forecast
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings data on Wednesday, February, 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $0.49. The biotechnology company had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative trailing twelve-month return on equity of 16,574.15%.

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (9.96%), Westfield Capital Management Co. LP (6.98%), Avoro Capital Advisors LLC (6.51%), Wellington Management Group LLP (5.63%), Capital International Investors (3.78%) and Massachusetts Financial Services Co. MA (2.63%).

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASND) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners